Online inquiry

IVTScrip™ mRNA-Human ARHGAP20, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK24986MR)

This product GTTS-WK24986MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARHGAP20 protein. This product can be used in Meiotic prophase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001258415.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 57569
UniProt ID Q9P2F6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARHGAP20, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK24986MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK25809MR IVTScrip™ mRNA-Human API5, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA API5
GTTS-WK11966MR IVTScrip™ mRNA-Human ADRA1D, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADRA1D
GTTS-WK26784MR IVTScrip™ mRNA-Human ARHGAP17, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP17
GTTS-WK8061MR IVTScrip™ mRNA-Human ADORA2B, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADORA2B
GTTS-WK26910MR IVTScrip™ mRNA-Human ASGR1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASGR1
GTTS-WK25975MR IVTScrip™ mRNA-Human ARRB1, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARRB1
GTTS-WK22201MR IVTScrip™ mRNA-Human APCDD1, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA APCDD1
GTTS-WK8366MR IVTScrip™ mRNA-Human ADRA1D, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADRA1D
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW